HC Wainwright Reiterates “Buy” Rating for AC Immune (NASDAQ:ACIU)

HC Wainwright reiterated their buy rating on shares of AC Immune (NASDAQ:ACIU) in a research report released on Friday,Benzinga reports. They currently have a $16.00 price objective on the stock.

AC Immune Stock Down 0.4 %

NASDAQ:ACIU opened at $2.29 on Friday. AC Immune has a twelve month low of $2.19 and a twelve month high of $4.98. The business has a 50 day moving average price of $2.61 and a two-hundred day moving average price of $2.98. The company has a market cap of $226.57 million, a P/E ratio of -4.98 and a beta of 1.23.

Hedge Funds Weigh In On AC Immune

A number of large investors have recently bought and sold shares of ACIU. Quinn Opportunity Partners LLC acquired a new position in AC Immune during the 4th quarter worth approximately $27,000. Two Sigma Advisers LP acquired a new position in AC Immune during the 4th quarter worth approximately $36,000. Boothbay Fund Management LLC acquired a new position in AC Immune during the 4th quarter worth approximately $38,000. RPO LLC acquired a new position in AC Immune during the 4th quarter worth approximately $51,000. Finally, Jane Street Group LLC acquired a new stake in shares of AC Immune in the 4th quarter valued at approximately $66,000. Institutional investors and hedge funds own 51.36% of the company’s stock.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.